Endocannabinoids and psychopathology: The therapy inside

Pharmacological Research

Volumn 56, Issue 5, 2007, Pages 357-359

  Drago, Filippo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Addiction; Anxiety; Depression; Endocannabinoids; Neurodegenerative diseases; Psychopathology

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; COCAINE; ENDOCANNABINOID; RIMONABANT;

ANXIETY DISORDER; BRAIN FUNCTION; CANNABIS ADDICTION; CLINICAL RESEARCH; COGNITION; DEGENERATIVE DISEASE; DEPRESSION; DRUG DEPENDENCE; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; HUMAN; MEMBRANE TRANSPORT; MENTAL DISEASE; MOTOR PERFORMANCE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

ENDOCANNABINOIDS; HUMANS; MENTAL DISORDERS; NEURODEGENERATIVE DISEASES; PSYCHOTROPIC DRUGS;

EID: 35648930404     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2007.09.007     Document Type: Editorial

References (28)

1. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
2. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215 (1995) 89-97
3. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50 (1995) 83-90
4. Di Marzo V., and Petrosino S. Endocannabinoids and the regulation of their levels in health and disease. Curr Opin Lipidol 18 (2007) 129-140
5. McFarland M.J., and Barker E.L. Anandamide transport. Pharmacol Ther 104 (2004) 117-135
6. Dinh T.P., Freund T.F., and Piomelli D. A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids 121 (2002) 149-158
7. Makara J.K., Mor M., Fegley D., Szabo S.I., Kathuria S., Astarita G., et al. Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat Neurosci 8 (2005) 1139-1141
8. Marsicano G., and Lutz B. Neuromodulatory functions of the endocannabinoid system. J Endocrinol Invest 29 (2006) 27-46
9. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4 (2003) 873-884
10. Lin H.C., Mao S.C., and Gean P.W. Effects of intra-amygdala infusion of CB1 receptor agonists on the reconsolidation of fear-potentiated startle. Learn Mem 13 (2006) 316-321
11. Kathuria S., Gaetani S., Fegley D., Valino F., Duranti A., Tontini A., et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9 (2003) 76-81
12. Gobbi G., Bambico F.R., Mangieri R., Bortolato M., Campolongo P., Solinas M., et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci 102 (2005) 18620-18625
13. Vinod K.Y., and Hungund B.L. Role of the endocannabinoid system in depression and suicide. Trends Pharmacol Sci 27 (2006) 539-545
14. Hill M.N., Ho W.S., Sinopoli K.J., Viau V., Hillard C.J., and Gorzalka B.B. Inolvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamo-pituitary-adrenal axis. Neuropsychopharmacology 31 (2006) 2591-2599
15. Mangieri R.A., and Piomelli D. Enhancement of endocannabinoid signalling and the pharmacotherapy of depression. Pharmacol Res 56 (2007) 360-366
16. Mikics E., Dombi T., Barsvari B., Varga B., Ledent C., Freund T.F., et al. The effects of cannabinoids on contextual conditioned fear in CB1 knockout and CD1 mice. Behav Pharmacol 17 (2006) 223-230
17. Lafenêtre P., Chaouloff F., and Marsicano G. The endocannabinoid system in the processing of anxiety and fear and how CB1 receptors may modulate fear extinction. Pharmacol Res 56 (2007) 367-381
18. Micale V., Mazzola C., and Drago F. Endocannabinoids and neurodegenerative diseases. Pharmacol Res 56 (2007) 382-392
19. Mazzola C., Micale V., and Drago F. Amnesia induced by beta-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade. Eur J Pharmacol 477 (2003) 219-225
20. Goodman J., and Gilman L. The pharmacological basis of therapeutics (2006), McGraw-Hill, New York p. 253
21. Solinas M., Yasar S., Steven R., and Goldberg S.R. Endocannabinoid system involvement in brain reward processes related to drug abuse. Pharmacol Res 56 (2007) 393-405
22. Van Sickle M.D., Duncan M., Kingsley P.J., Mouihate A., Urbani P., Mackie K., et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310 (2005) 329-332
23. Tanda G. Modulation of the endocannabinoid system: therapeutic potential against cocaine dependence. Pharmacol Res 56 (2007) 406-417
24. Gonzalez S., Cascio M.G., Fernandez-Ruiz J., Fezza F., Di Marzo V., and Ramos J.A. Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res 954 (2002) 73-81
25. Cheer J.F., Wassum K.M., Sombers L.A., Heien M.L., Ariansen J.L., Aragona B.J., et al. Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation. J Neurosci 27 (2007) 715-791
26. Mailleux P., and Vanderhaeghen J.J. Distribution of the neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 48 (1992) 655-688
27. Fattore L., Fadda P., and Fratta W. Role of the endocannabinoid system in relapse to drug addiction. Pharmacol Res 56 (2007) 418-427
28. Bisogno T., and Di Marzo V. Short- and long-term plasticity of the endocannabinoid system in neuropsychiatric and neurological disorders. Pharmacol Res 56 (2007) 428-442